ARSUF Fagron N.V.
OTCHealthcareAs of 2026-08-21 16:00
Why ARSUF matters now
Fagron N.V. (ARSUF) is a US stock in Healthcare. The latest InvestLog snapshot shows $27.00 with -1.82% on the session and $1.98B in market capitalization.
The latest indexable market news headline is "Fagron NV (ARSUF) Q2 2026 Earnings Call Transcript" from Seeking Alpha.
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
BE
Exchange
OTC
Beta
0.39
Fagron N.V. is a specialized pharmaceutical compounding firm focused on delivering tailored medicinal solutions. The company caters to a diverse range of clients, including hospitals, pharmacies, clinics, and individual patients. Beyond providing direct services, Fagron N.V. actively drives innovation by developing cutting-edge concepts, delivery methods, and specific formulations for pharmaceutical compounding. Its extensive product line includes essential raw materials, specialized tools and equipment, semi-finished goods, various drug vehicles, and both sterile and non-sterile custom-prepared medications. Furthermore, the company supports professional development through the Fagron Academy, offering comprehensive education and training programs for medical prescribers and pharmacists. With a significant global presence, Fagron N.V. operates across Latin America, North America, Europe, the Middle East, and Africa. Founded in 1990 and headquartered in Nazareth, Belgium, the company underwent a name change in January 2015, rebranding from its former identity, Arseus N.V., to Fagron N.V.